NVSNovartis PharmaceuticalsRunning, no new patients
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 180 (planned)
- Started
- Feb 7, 2025
- Main results expected
- Feb 25, 2028
- Fully finished
- Feb 26, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living (MG-ADL) total score
Measured over: Baseline to Month 6
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06744920 · record last updated 2026-09-28 · checked 2026-11-09 15:47 UTC